- A 2026 BMJ study of 2,297,942 Ontario adults aged 66 and over found that 10.9% of people newly started on a statin were dispensed a prescription pain reliever within a year โ the second most common of 65 "prescribing cascades" the authors screened for
- A cascade is when a side effect gets treated as a new disease. Statin ache leads to a painkiller instead of a look at the statin. The study is observational signal detection: it can't prove any individual prescription was a cascade, and over-the-counter painkillers weren't counted
- Most statin aches aren't the statin. In the SAMSON trial, 90% of the symptom burden on atorvastatin was also present on placebo. Across 19 blinded trials and 123,940 people, 27.1% on statins reported muscle pain or weakness, against 26.6% on placebo
- The cost of getting it wrong is real. NSAIDs carry an FDA boxed warning for heart attack, stroke and gastrointestinal bleeding, can raise blood pressure and strain the kidneys, and older adults are at higher risk of all three
- The better path: never stop a statin on your own; ask for a proper workup (timing, CK if warranted, interacting drugs, thyroid, vitamin D), then a lower dose, a different statin or alternate-day dosing. Fewer than 5% of people are truly unable to take any statin, and there are proven alternatives for them
It's a familiar sequence. A man in his sixties starts a statin after a cholesterol check. A month later his thighs ache and his shoulders feel stiff. He mentions it at his next visit, or doesn't, and leaves with a prescription for an anti-inflammatory. Nobody has asked whether the statin dose is right, whether the ache is even the statin, or what a daily painkiller does to a 66-year-old's stomach, kidneys and blood pressure.
Geriatricians have a name for this: a prescribing cascade. A side effect of one drug is read as a new condition, and a second drug is added to treat it. In September 2026, a Toronto-led research team, working with data held at ICES, published a province-wide attempt to measure how often it happens, across an entire province's older population (Rochon et al., BMJ 2026). The statin-to-painkiller sequence was near the top of the list. This article explains what they found, why the ache is usually not what it seems, and what a sensible conversation with your doctor looks like.
Sixty-Five Cascades, 2.3 Million People
Evidence: Moderate โ very large population cohort, signal detection onlyThe study started with a list, not with patients. In 2025, an international panel of 12 experts in prescribing for older adults, drawn from eight countries, agreed on 65 "potentially inappropriate prescribing cascades" worth watching for. The team then looked for each of them in health administrative data on 2,297,942 community-dwelling Ontario adults aged 66 and over (54.3% women, 12.8% aged 85 or more), among people newly started on the first drug between 1 January 2022 and 31 December 2023 under the province's drug benefit programme.
For each cascade they measured three things: how common the first drug was in the population, how often new users of it went on to start the second drug within a year, and a statistic called the adjusted sequence ratio. The ratio compares the number of people who started drug B after drug A with the number who started B before A. If the two drugs were unrelated, the sequence would be random and the ratio about 1. The more it rises above 1, the more the order suggests that A is leading to B. Twenty-four of the 65 cascades met all three prioritisation criteria: an initial drug used by at least 5% of the population, a cascade incidence of at least 1%, and an adjusted ratio above 1, each with the lower bound of its confidence interval clearing the threshold.
Cardiovascular drugs were the most common initiating drugs. Antihypertensives led (65.9% of the source population), and statins were close behind, dispensed to 62.6% of the men and 48.5% of the women. Three cascades stood out for incidence.
The three most common cascades: share of new users of the first drug who started the second within a year
One-year incidence with 95% confidence intervals: iron to laxative 11.7โ12.1%; statin (HMG-CoA reductase inhibitor) to pain reliever 10.7โ11.0%; cholinesterase inhibitor (a dementia drug) to sleep agent 9.9โ10.7%. New users of the first drug identified in 2022โ2023, followed for one year, among Ontario residents aged 66+. Over-the-counter drugs were not counted.
Incidence tells you how often the pair happens; the sequence ratio tells you whether the order is suspicious. For statin to pain reliever, 19,339 people started the painkiller after the statin and 18,144 started it before, a crude ratio of 1.07; after correcting for a background prescribing trend that ran the other way (null-effect ratio 0.92), the adjusted sequence ratio was 1.16 (95% CI 1.14โ1.19). That is a modest but clear signal, in the same range as iron to laxative (1.17) and several cascades that start with an NSAID painkiller itself.
How much more often the second drug followed the first than preceded it: adjusted sequence ratios
Bar length shows the excess above 1.0, where 1.0 would mean the two drugs were started in random order. The adjusted ratio divides the crude ratio by a "null effect" ratio that corrects for trends in how often each drug was being prescribed. 34 of the 65 cascades had an adjusted ratio above 1.0. Note that NSAIDs show up as the first drug in three cascades of their own.
Read that last point twice. If a statin ache is treated with an NSAID, the patient is now at the head of three further cascades the same study flags: NSAID to a stomach-protecting drug, NSAID to a heart failure drug and NSAID to a blood pressure drug. One misread side effect can become four prescriptions.
The authors are explicit about the limits. Prescription sequence symmetry analysis is, in their words, a "relatively crude but efficient screening method". It doesn't imply causation, it doesn't fully account for confounding by indication, and the paper didn't look at what happened to patients afterwards. Over-the-counter drugs weren't captured, so the true number of statin users reaching for a painkiller is almost certainly higher than 10.9%. The main text also doesn't spell out which drugs count as a "pain reliever" (the appendix does), so treat it as a broad category rather than NSAIDs specifically.
Why Most Statin Aches Aren't the Statin
Evidence: Strong โ blinded randomised trials and a 123,940-person meta-analysisHere is the uncomfortable part for anyone who has felt it: muscle symptoms on statins are real, common, and mostly not caused by the drug. Two pieces of evidence make the case, and they come from opposite ends of the size spectrum.
The first is small and ingenious. The SAMSON trial recruited 60 people (mean age 65) who had stopped a statin within two weeks of starting because of side effects, most often muscle aches. Each was given 12 bottles, one per month in random order: four containing atorvastatin 20 mg, four containing an identical placebo, and four empty. Every day for a year they rated their symptoms from 0 to 100 on a phone app, and they could stop any month's tablets if symptoms became intolerable (American College of Cardiology summary; published as Wood, Howard et al., NEJM 2020).
Average symptom intensity, 0โ100, in months on no tablet, placebo and atorvastatin
60 patients who had previously quit statins, each assigned four months on each arm in random order (49 completed all 12 months). 95% confidence intervals: no tablets 4.7โ11.3; placebo 12.1โ18.7; statin 13.0โ19.6. The statin-versus-placebo difference was not statistically significant. The "nocebo ratio", the share of the symptom burden on statin that was also produced by placebo, was 0.90.
Taking a tablet roughly doubled symptom scores, whether or not the tablet contained a drug. Ninety per cent of the symptom burden on atorvastatin was reproduced by placebo. Six months after the trial ended, having seen their own results, 30 of the 60 participants (50%) had restarted a statin. That isn't the drug being harmless; it's the expectation of harm producing real, measurable symptoms, a phenomenon known as the nocebo effect.
The second piece of evidence is the opposite kind of study. The Cholesterol Treatment Trialists' Collaboration pooled individual records from 19 double-blind, placebo-controlled statin trials with 123,940 participants, followed for a weighted average of 4.3 years, plus four trials comparing more and less intensive regimens in 30,724 people (CTT Collaboration, Lancet 2022). Muscle pain or weakness was reported by 27.1% of people on a statin and 26.6% on placebo. The relative risk was 1.03 overall (95% CI 1.01โ1.06), 1.07 in the first year (1.04โ1.10) and 0.99 after that (0.96โ1.02). In absolute terms the first-year excess was 11 events per 1,000 person-years, and the authors calculated that only about one in 15 muscle-symptom reports from statin users in year one was actually due to the statin. More intensive regimens (atorvastatin 40โ80 mg or rosuvastatin 20โ40 mg) carried a slightly larger excess, a relative risk of 1.08 versus 1.03 for moderate regimens. Statins produced only a small, clinically insignificant rise in creatine kinase, the muscle-damage enzyme.
Put the two together and the picture is consistent. Statins do cause muscle symptoms in a minority of people, mostly in the first year and mostly mild, and the risk rises a little with dose. But the great majority of aches reported by statin users would have happened on a placebo. That is exactly the kind of symptom that invites a cascade: real enough to prescribe for, but not usually caused by the drug being blamed.
What a Painkiller Costs at 66
Evidence: Strong โ FDA labelling and geriatric prescribing criteriaIf the second drug were harmless, a cascade would be an inefficiency. With NSAIDs in older adults, it isn't. In 2015 the FDA strengthened its warning that non-aspirin NSAIDs โ ibuprofen, naproxen, diclofenac, celecoxib and the rest โ can cause heart attacks or strokes. The risk "can occur as early as the first weeks of using an NSAID", "may increase with longer use" and "appears greater at higher doses". People with heart disease or its risk factors, which describes almost everyone on a statin, have a greater likelihood of heart attack or stroke after NSAID use (FDA Drug Safety Communication, 9 July 2015).
The prescribing information for any prescription NSAID carries a boxed warning on two fronts: "NSAIDs may cause an increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke" and "NSAIDs cause an increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation", adding that "elderly patients are at greater risk for serious gastrointestinal events". The same label warns that NSAIDs "can lead to onset of new hypertension or worsening of pre-existing hypertension", and that patients at greatest risk of kidney injury are "those with impaired renal function, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors, and the elderly". Patients with a previous ulcer or GI bleed have "a greater than 10-fold increased risk for developing a GI bleed". The label's advice is that "the lowest effective dose should be used for the shortest possible duration" (meloxicam prescribing information, DailyMed).
The American Geriatrics Society's 2023 Beers Criteria, the standard US list of drugs to avoid or use with caution in people 65 and over, take the same view: avoid chronic NSAID use unless other alternatives are ineffective and the patient can take a stomach-protecting drug, and avoid even short-term use in certain situations where drug interactions are present (2023 AGS Beers Criteria, summarised by the University of Illinois Chicago College of Pharmacy). Set that against Figure 2: the three NSAID cascades the Ontario study flagged โ to a stomach protector, a heart failure drug and a blood pressure drug โ look like the label's warnings showing up in prescription records, though the method can only flag the pattern, not prove it.
None of this means an older adult can never take an anti-inflammatory. It means a daily NSAID is not a casual add-on, and it is a poor answer to a symptom that, nine times in ten, isn't the statin's fault.
What a Proper Workup Looks Like
Evidence: Strong โ National Lipid Association 2022 scientific statementThe National Lipid Association's 2022 scientific statement sets out how statin intolerance should be defined and handled (Cheeley et al., Journal of Clinical Lipidology 2022, summarised by the ACC; NLA infographic). Its central rule: nobody should be labelled statin intolerant until at least two statins have been tried, including one at the lowest approved daily dose. Myalgia is reported by 5โ30% of statin users depending on the population, but true myopathy, with unexplained symptoms and creatine kinase more than 10 times the upper limit of normal, occurs in roughly 1 in 10,000 patients a year, and rhabdomyolysis in about 1 in 100,000. Complete intolerance, the inability to take any statin at any dose, affects fewer than 5% of patients. The NLA's words: "most patients can tolerate some degree of statin therapy (agent, dose and/or regimen) if they experience symptoms", and "the effort to identify a tolerable statin treatment regimen should not be abandoned".
What should happen before anyone prescribes a painkiller
| Step | What it involves | Why |
|---|---|---|
| 1. Describe the symptom | When it started relative to the statin, where it is, whether it's symmetrical, whether there's weakness or dark urine | Timing and pattern are what your doctor uses to judge whether the drug is the likely cause; a sore knee that began after gardening is a different question |
| 2. Creatine kinase (CK) | A blood test, if symptoms are severe, there's weakness, or dark urine CK >10ร upper limit = myopathy; >40ร = rhabdomyolysis | Separates the rare dangerous reaction (stop the statin) from the common benign one |
| 3. Look for other causes | Thyroid function, vitamin D, alcohol, strenuous new exercise, obesity, diabetes | The NLA lists these as modifiable factors that can cause or worsen symptoms |
| 4. Check interacting drugs | Gemfibrozil, amiodarone, some calcium channel blockers, azole antifungals, macrolide antibiotics, protease inhibitors, immunosuppressants, colchicine | These raise statin blood levels and make genuine muscle effects more likely |
| 5. Re-trial | Lower dose; a different statin; alternate-day or non-daily dosing; brief pause and re-challenge to see if the ache tracks the drug | Most people find a tolerable regimen; complete intolerance is under 5% |
| 6. If still intolerant | Ezetimibe; bempedoic acid; PCSK9 inhibitor, prioritising drugs proven to cut cardiovascular events in trials | Keeps LDL down without the statin; doesn't leave high cholesterol untreated |
Based on the 2022 NLA scientific statement on statin intolerance and the 2022 CTT meta-analysis. Steps 1โ3 and 5 are for your doctor to lead; your job is to report accurately and not to stop the statin unilaterally. Dark urine with muscle pain is a same-day call.
The re-trial step is where a cascade should stop. A dose cut or a switch to a different statin resolves many complaints; alternate-day dosing is the NLA's recognised option for the rest. If symptoms don't track the drug on a blinded or structured re-challenge, that's useful information too: it means the painkiller was never the answer, because the statin was never the question.
When a statin genuinely won't work
For the minority who can't tolerate any statin, cholesterol still needs lowering, and the evidence for the alternatives is now solid. Ezetimibe lowers LDL by 13โ20% with a low rate of side effects, and the 2018 AHA/ACC cholesterol guideline says it may be reasonable to use LDL-lowering drugs proven safe and effective in randomised trials for people who cannot tolerate the recommended statin intensity (Grundy et al., Circulation 2019). Bempedoic acid was tested in exactly this group: the CLEAR Outcomes trial randomised 13,970 patients who had declared in writing that they could not tolerate statins to bempedoic acid 180 mg or placebo. Over a median of 40.6 months, LDL fell by about 21% and the four-part composite of cardiovascular death, heart attack, stroke or coronary revascularisation was 13% lower (hazard ratio 0.87, 95% CI 0.79โ0.96), with heart attacks down 23%. Gout and gallstones were each about 1 percentage point more common on the drug (ACC review of CLEAR Outcomes; Cleveland Clinic Journal of Medicine; Nissen et al., NEJM 2023). PCSK9 inhibitors go further on LDL: in GAUSS-3, 491 patients with muscle symptoms on two or more statins went through a blinded atorvastatin-versus-placebo crossover, 209 (42.6%) had symptoms on atorvastatin but not placebo, and among those confirmed intolerant, evolocumab lowered LDL by 52.8% over 24 weeks against 16.7% for ezetimibe (ACC summary of GAUSS-3; Nissen et al., JAMA 2016).
The NLA's guidance on choosing among them is simple: favour non-statin drugs that have reduced cardiovascular events in randomised trials, and in high-risk patients consider starting one while the search for a tolerable statin continues, rather than leaving LDL high for months.
Questions to Ask, and When a Painkiller Is Fine
A cascade is easiest to stop at the moment the second prescription is being written. Five questions do most of the work:
- "Could this be the statin?" Say the words. Timing matters: symptoms that began within weeks of starting or raising the dose deserve a look; an ache that began a year in, after a new gym routine, probably isn't the drug.
- "Should we check a CK?" Especially if there's weakness, the pain is severe or your urine has darkened.
- "Is anything else I take interacting with it?" Bring the full list, including supplements and over-the-counter drugs.
- "Can we try a lower dose, a different statin or every-other-day dosing before adding anything?" This is the NLA's recommended sequence, and it's the step a prescribing cascade skips.
- "If I do need a painkiller, which one, for how long, and what should it do to my blood pressure and kidneys?" If the answer is an NSAID for an open-ended period, ask what the alternative is.
Sometimes a pain reliever after a statin is entirely reasonable. Older adults get arthritis, injuries and back pain regardless of statins, and the study's own numbers say the order statin-then-painkiller was only 16% more common than the reverse after adjustment. A short course of acetaminophen for a flare, or a brief NSAID course with a clear stop date in someone with healthy kidneys and no ulcer history, is ordinary medicine. The Ontario authors themselves suggest acetaminophen as the substitution for an NSAID in the NSAID-to-blood-pressure-drug cascade. The cascade is the open-ended prescription written instead of the conversation above.
Two final points. First, the point of a statin is to lower the particles that drive plaque, and if the number you're treating is LDL alone, ask about apolipoprotein B and lipoprotein(a) too; we cover both in Half of Healthy Adults Have Plaque. Two Tests to Ask For. Second, and most important: do not stop a statin on your own. The CTT data put the real muscle risk at about one extra report per 90 people in the first year, nearly all mild, against a drug that prevents heart attacks and strokes. If the ache is bad enough to act on, it's bad enough for a phone call first.
Frequently Asked Questions
Treat the cause, not the symptom of the treatment.
One in nine older adults who start a statin is dispensed a painkiller within the year, and the order of the two prescriptions is skewed enough to suggest that some of those are side effects being treated as diseases. Yet blinded trials show nine in ten statin aches would have happened on a sugar pill, and the anti-inflammatories often added carry their own warnings for the heart, stomach and kidneys.
The way out is a conversation, not a second prescription. Report the symptom precisely, ask for the workup, try a different dose or statin, and if nothing works, use an alternative that has been shown to prevent heart attacks. Whatever you do, don't quietly stop the statin. This article is not medical advice; take it to your doctor.
Sources
- Rochon PA, Austin PC, Gurwitz JH, et al. Exploring high priority potentially inappropriate prescribing cascades in older adults: population level retrospective cohort study. BMJ 2026;394:e100499, published 10 September 2026 (doi:10.1136/bmj-2026-100499). Sequence ratios from Table 3.
- Wood FA, Howard JP, Finegold JA, et al. N-of-1 trial of a statin, placebo, or no treatment to assess side effects. New England Journal of Medicine 2020;383:2182โ2184. Results as reported by the American College of Cardiology, the British Heart Foundation (the trial's funder) and TCTMD.
- Cholesterol Treatment Trialists' Collaboration. Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials. Lancet 2022;400:832โ845 (abstract via NHLBI BioLINCC; PMC7613583).
- US Food and Drug Administration. FDA Drug Safety Communication: FDA strengthens warning that non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs) can cause heart attacks or strokes. 9 July 2015.
- Meloxicam tablets, prescribing information (Dr. Reddy's Laboratories). DailyMed, US National Library of Medicine.
- 2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society 2023;71:2052โ2081. NSAID recommendation as summarised by the University of Illinois Chicago College of Pharmacy.
- Cheeley MK, Saseen JJ, Agarwala A, et al. NLA scientific statement on statin intolerance. Journal of Clinical Lipidology 2022. ACC: Ten points to remember; NLA infographic.
- Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. Circulation 2019 (doi:10.1161/CIR.0000000000000625).
- Nissen SE, Lincoff AM, Brennan D, et al. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients. New England Journal of Medicine 2023;388:1353โ1364. Results as reported by the American College of Cardiology and the Cleveland Clinic Journal of Medicine.
- Nissen SE, et al. GAUSS-3: evolocumab vs ezetimibe in patients with muscle-related statin intolerance. JAMA 2016. Results as reported by the American College of Cardiology.